New York University;Salk Institute for Biological Studies
发明人:
Mohammadi, Moosa,Goetz, Regina,Evans, Ronald M.,Downes, Michael,Suh, Jae Myoung
申请号：
AU2013271471
公开号：
AU2013271471A1
申请日:
2013.06.06
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor ("FGF") and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βΚΙοthο-FGF receptor complex involving the use of chimeric proteins of the present invention.
